BTI
KYMR icon

Blue Trust Inc’s Kymera Therapeutics KYMR Stock Holding History

Blue Trust Inc’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-247
Closed -$6.76K – 2544
2025
Q1 		$6.76K Hold
247
– – ﹤0.01% 2044
2024
Q4 		$9.94K Sell
247
-114
-32% -$5.15K ﹤0.01% 1876
2024
Q3 		$10.8K Buy
361
+83
+30% +$3.67K ﹤0.01% 2171
2024
Q2 		$11.2K Buy
+278
New +$9.63K ﹤0.01% 1895
2023
Q3 		– Sell
-20
Closed -$1K – 2179
2023
Q2 		$1K Buy
20
+7
+54% +$201 ﹤0.01% 1875
2023
Q1 		$0 Sell
13
-8
-38% -$258 ﹤0.01% 2485
2022
Q4 		$0 Sell
21
-79
-79% -$2.11K ﹤0.01% 2357
2022
Q3 		$2K Buy
+100
New +$2.64K ﹤0.01% 1798

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Blue Trust Inc's KYMR Position: Q2 2025 in Review

Blue Trust Inc sold out of Kymera Therapeutics (KYMR) in Q2 2025, closing a stake of 247 shares — an estimated $6.76K sold.

Blue Trust Inc first reported a position in KYMR in Q3 2022 and held it in 8 quarters. The position peaked at $11.2K in Q2 2024. 210 funds tracked by Wall St. Rank hold KYMR as of Q2 2025.

  • Blue Trust Inc reported no remaining Kymera Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Blue Trust Inc sold 247 Kymera Therapeutics shares in Q2 2025, an estimated $6.76K.
  • Blue Trust Inc first reported a position in Kymera Therapeutics in Q3 2022 and held it in 8 quarters.
  • Blue Trust Inc's Kymera Therapeutics position peaked at $11.2K in Q2 2024.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2025.

Based on Blue Trust Inc's 13F filing for Q2 2025, filed 24 Jul 2025.